Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
Part of paid clinical trials in Columbus, Ohio.
- Sponsor
- Esanex Inc.
- Study ID
- NCT02914327
- Phase
- PHASE1
- Status
- Withdrawn
Conditions
- Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- SNX-5422 plus ibrutinib — DRUGSNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
Study Details
SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the addition of SNX-5422 to an established dose of ibrutinib will result in the removal of mutated BTK from blood mononuclear cells and/or prevents or delays disease progression of subjects with CLL
Key Dates
- Start date
- Feb 2, 2017
- Status verified
- Jul 2018
- Primary completion
- Jul 1, 2018
- Completion
- Jul 1, 2018
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: SNX-5422 plus ibrutinibOpen-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule until the cancer progresses or the subject is unable to tolerate the therapy
Primary Outcome Measure
Efficacy of the combination of SNX-5422 and ibrutinib [ Time Frame: Every 12 weeks up to 52 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Wexner Medical Center, Ohio State University | Columbus | Ohio | 43210 | - |
Find similar trials in Columbus, OH
By research site
Related Studies
- Childhood Cancer Survivor StudyRecruiting · St. Jude Children's Research Hospital · Birmingham, Alabama
- Caris Biorepository Research ProtocolRecruiting · Caris Science, Inc. · Mobile, Alabama
- Precision Cancer Medicine for Advanced Cancer Through High-throughput SequencingRecruiting · Ohio State University Comprehensive Cancer Center · Columbus, Ohio
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama